New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
09:00 EDTEPZMEpizyme rises 46.3%
Epizyme is up 46.3%, or $9.50, to $30.00
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
10:12 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information
August 13, 2014
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
August 12, 2014
17:12 EDTEPZMEpizyme reports MTD not reached in 3 dose cohorts from EPZ-6438 Phase 1 trial
Subscribe for More Information
15:56 EDTEPZMEpizyme rises 5.3% to $35.93
A late day move higher in shares of Epizyme came in concert with the posting of a presentation dated August 12, entitled "EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations," to the company's website. Reference Link
15:23 EDTEPZMNotable companies reporting before tomorrow's open
Subscribe for More Information
August 11, 2014
06:54 EDTEPZMAmerican Society of Hematology to hold a meeting
Subscribe for More Information
August 7, 2014
15:31 EDTEPZMEpizyme management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use